Ghent University Academic Bibliography

Your filters: cql: author="van Dam, Peter A." or (type any "bookEditor issueEditor" and editor="van Dam, Peter A.")

Add to list
- Miscellaneous
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).
Add to list
- Journal Article
- A1
- open access
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Emiel De Jaeghere (UGent) , Hannelore Hamerlinck (UGent) , Sandra Tuyaerts, Lien Lippens (UGent) , An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286
Add to list
- Journal Article
- A1
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491
Add to list
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, Ann M.T. van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188
Add to list
- Journal Article
- A1
- open access
Anthracyclines strike back : rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

Francesco Schettini, Mario Giuliano, Matteo Lambertini, Rupert Bartsch, David James Pinato, Concetta Elisa Onesti, Nadia Harbeck, Diana Lueftner, Sylvie Rottey (UGent) , Peter A. van Dam, et al.

(2021) CANCERS. 13(17).
Add to list
Use of the levonorgestrel-releasing intrauterine system in breast cancer patients

Xuan Bich Trinh, Wiebren A. A. Tjalma, Amin Makar (UGent) , Guy Buytaert, Joost Weyler and Peter A. van Dam

(2008) FERTILITY AND STERILITY. 90(1). p.17-22

Academic Bibliography

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Anthracyclines strike back : rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

Use of the levonorgestrel-releasing intrauterine system in breast cancer patients

Contents

Support

Contact